Glass Wall Systems IPO
₹172 – ₹172 · Issue Size ₹423 CrIPO Overview
Business Model
- Market leadership supported by a diversified business model and strong foothold in domestic and international
- We are the second largest provider of façade solutions in India in terms of revenue in Fiscal 2025 and Fiscal 2024.
- (Source: Ken Report) We are also India’s largest façade exporter in 2024 in terms of revenue. (Source: Ken Report)
- Our expertise in designing and manufacturing innovative and sustainable façade systems makes us a preferred partner
- We have strategically structured our operations to ensure a healthy mix of domestic business that includes
IPO Timeline
Risk Factors
(formerly known as IIFL Securities Limited) Gaurav Mittal / Pavan
India Private Limited) Shanti Gopalkrishnan Telephone: +91 810 811 4949 E-mail:
Strengths & Weaknesses
Strengths
- Market leadership supported by a diversified business model and strong foothold in domestic and international
- We are the second largest provider of façade solutions in India in terms of revenue in Fiscal 2025 and Fiscal 2024.
- (Source: Ken Report) We are also India’s largest façade exporter in 2024 in terms of revenue. (Source: Ken Report)
- Our expertise in designing and manufacturing innovative and sustainable façade systems makes us a preferred partner
- We have strategically structured our operations to ensure a healthy mix of domestic business that includes
Weaknesses
- IIFL Capital Services Limited
Management & Promoters
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| Glass Wall Systems IPO | — | — |
| Telephone: + | 91.0x | — |
| Telephone: + | 91.0x | — |
| Telephone: + | 91.0x | — |
| Dated September | 5.0x | — |
| Please read Section of the Companies Act | 32.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| March 2024 | ₹1.4 Cr | ₹3.1 Cr | ₹312.13 Cr | — |
| March 2023 | ₹201.5 Cr | ₹202.4 Cr | ₹312.13 Cr | — |
| March 2025 | ₹-1.6 Cr | ₹2.9 Cr | ₹3.1 Cr | — |
| June 2025 | ₹196.1 Cr | ₹312.13 Cr | ₹202.4 Cr | — |
| October 2021 | — | ₹312.13 Cr | ₹312.13 Cr | — |
About
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medica
Key Regulations and Policies in India", "History and Certain Corporate Matters", "Restated Financial Information", "Outstanding Litigation and Other Material Developments", "Offer Procedure" and "Articles of Association" on pages 119, 138, 146, 156, 279, 287, 323, 475, 507 and 531, respectively, will have the meaning ascribed to such terms in those respective sections. General terms Term Description our Company / the Company / the Issuer Glass Wall Systems (India) Limited, a public limited company, that was incorporated under the Companies Act, 1956 and having its Registered and Corporate
| Exchange | NSE |
| Issue Type | mainboard |
| Face Value | ₹2 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.